Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939940 | 0.86 | PDGFRB (0.49) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL207052 | 0.84 | ERN1 (0.50) | ALDH1A1PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL30000843 | 0.84 | PDGFRB (0.45) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL505591 | 0.84 | PDGFRB (0.48) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL11066620 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL505294 | 0.83 | KDM4E (0.57) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL505205 | 0.83 | TDP1 (0.47) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL9084161 | 0.83 | PKM (0.44) | LMNAPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL505648 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL16935287 | 0.83 | PDGFRB (0.44) | ALDH1A1PDGFRBFGFR1PDGFRAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| WO-2025023769-A1 | NOVEL SYNTHESIS METHOD OF 18F-RUCAPARIB | 고려대학교 산학협력단 | 2025-01-30 | — | — | WO | disclosed |
| WO-2024231852-A1 | SUBSTITUTED BIPHENYL COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-11-14 | — | — | WO | disclosed |
| CN-113544129-B | Tricyclic compound preparation method and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| EP-3585772-B1 | 1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | MERCK PATENT GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| CN-116669744-A | Nrf2 activating compounds | 千寿制药株式会社 | 2023-08-29 | — | — | CN | disclosed |
| CN-110325514-B | 1,4, 6-trisubstituted-2-alkyl-1H-benzo [ d ] imidazole derivatives as dihydroorotate oxygenase inhibitors | 默克专利有限责任公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1511482-B1 | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1709015-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| CN-1674898-A | 2-ureido-6-heteroaryl-3H-benzimidazole-4-carboxylic acid derivatives and related compounds as inhibitors of gyrase and/or topoisomerase I V for the treatment of bacterial infections | VERTEX PHARMA (US) | 2005-09-28 | — | — | CN | disclosed |
| WO-2005070906-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| EP-1511482-A1 | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003105846-A1 | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | ALDH1A1 555/4885LMNA 2078/4885PDGFRB 1770/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | ALDH1A1 1717/4885LMNA 679/4885PDGFRB 788/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | ALDH1A1 790/4885LMNA 3058/4885PDGFRB 3152/4885 |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | ALDH1A1 756/4885LMNA 2635/4885PDGFRB 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.